Anticancer Drug Applications
Anticancer Drug Applications - Related Videos
09:39
Assessing Specificity of Anticancer Drugs In Vitro
0 Views •
Cited by 8 •
2016
The goal of this protocol is to assess specificity of anticancer drugs in vitro using mixed cultures containing both tumor and non-tumor cells.
08:03
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
0 Views •
Cited by 7 •
2016
Photodynamic therapy (PDT) is an alternative choice for lung cancer treatment. To increase the therapeutic effect of PDT, lung cancer-targeted nanoparticles combined with chemotherapy were developed. Both in vitro and in vivo anticancer efficacies of PDT with prepared nanoparticles were evaluated.
01:49
An Assay To Evaluate the Anticancer Effects of Lactobacillus Cell-Free Supernatant
0 Views •
2025
This video demonstrates an in vitro assay to study the anticancer effects of Lactobacillus cell-free supernatant (LCFS). Upon exposing colorectal cancer spheroids to varying doses of LCFS, the interaction with the bacterial metabolites in LCFS induces apoptosis in the cancer cells, disrupting the spheroid structure and leading to cell death in a dose-dependent manner.
09:03
Manufacture and Drug Delivery Applications of Silk Nanoparticles
0 Views •
Cited by 49 •
2016
Nanoparticles are emerging as promising drug delivery systems for a broad range of indications. Here, we describe a simple yet powerful method to manufacture silk nanoparticles using reverse engineered Bombyx mori silk. These silk nanoparticles can be readily loaded with a therapeutic payload and subsequently explored for drug delivery applications.
15:04
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
0 Views •
Cited by 3 •
2019
This protocol describes how to assess synergism between an anticancer antibody and antineoplastic drugs in preclinical models by using the combination index equation of Chou and Talalay.
FAQs
Some anticancer drugs act by disrupting DNA replication, preventing malignant cells from accurately copying their genetic material. Others interfere with cell division, limiting the production of additional tumor cells. These mechanisms can reduce tumor growth because rapidly multiplying cells depend on coordinated DNA copying and division. Their effects also help researchers compare how different drug classes influence cancer-cell behavior.
Tumor growth can depend on hormone or growth-factor signaling, which transmits biological instructions that support malignant-cell survival or proliferation. Drugs that block these signals may be useful when a tumor’s characteristics indicate reliance on that pathway. Studying these dependencies connects drug action with tumor biology and supports treatment selection based on molecular biomarkers.
Immunotherapy works by activating immune responses against tumor cells rather than relying only on direct disruption of DNA replication, cell division, or signaling. This distinction makes the immune system an active participant in treatment. In cancer biology, comparing these mechanisms helps explain why combination therapies may be investigated and why treatment responses can vary among tumors.
Molecular biomarkers provide information about characteristics within a tumor that may guide treatment choices. They can help researchers and clinicians connect a drug’s mechanism, such as blocked signaling or immune activation, with features of a particular cancer. This personalized approach aims to match therapy more closely to tumor biology and supports investigation of why some treatments work better in selected cases.
Applications may include controlling malignant disease, eliminating cancer cells, shrinking tumors, or preventing recurrence after an initial response. The relevant goal depends on how the medication is being used and what outcome is being evaluated. Considering these outcomes allows researchers to distinguish short-term changes in tumor size from longer-term effects on disease control and recurrence.
Cancer-drug research examines treatment resistance because tumors may not remain equally responsive over time. Investigators also study combination therapies to evaluate whether drugs with different mechanisms can be used together, such as approaches affecting replication, signaling, hormones, or immune responses. These studies connect biological mechanisms with treatment outcomes and may reveal ways to improve control of tumor growth.